An exploratory imaging substudy of a 32-week randomised trial finds semaglutide and empagliflozin each lower cortical apparent diffusion coefficient and reduce total kidney volume in type 2 diabetes. PICO summary and expert commentary.
PIONEER 11 found that oral semaglutide monotherapy lowered HbA1c at all doses versus placebo in drug-naive, predominantly Chinese adults with type 2 diabetes, with weight reduction confined to the 7 mg and 14 mg doses. PICO summary and expert commentary.
A post-hoc pooled analysis of four semaglutide trials reports fewer worsening heart failure events in participants with HFpEF, with no significant effect on cardiovascular death. PICO summary and expert commentary.
A prespecified analysis of the FLOW randomised trial found once-weekly semaglutide reduced heart failure events and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. PICO summary and expert commentary.
A prespecified mortality analysis of the SELECT trial found that semaglutide 2.4 mg lowered all-cause death in adults with obesity and cardiovascular disease but no diabetes. PICO summary and expert commentary.
A secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials shows semaglutide 2.4 mg improves symptoms, weight, and exercise capacity in obesity-related HFpEF consistently across baseline C-reactive protein strata. PICO summary and expert commentary.
Prespecified subgroup analysis of the pooled STEP-HFpEF Program testing whether atrial fibrillation modifies semaglutide's effect on symptoms in obesity-related HFpEF. PICO summary and expert commentary.
An echocardiography substudy of the STEP-HFpEF Program found once-weekly semaglutide 2.4 mg attenuated adverse cardiac remodeling versus placebo over 52 weeks. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
